Postprandial insulin resistance as an early predictor of cardiovascular risk

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 761-770

  Lautt, W Wayne ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

HISS; Hyperglycemia; Hyperinsulinemia; Hyperlipidemia; Oxidative stress

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATROPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GONADOTROPIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE SYNTHASE INHIBITOR; PROINSULIN; REACTIVE OXYGEN METABOLITE; S ADENOSYLMETHIONINE; TESTOSTERONE; TRIACYLGLYCEROL;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIABETES MELLITUS; DIET RESTRICTION; EARLY DIAGNOSIS; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NONHUMAN; OXIDATIVE STRESS; POSTPRANDIAL STATE; PROTEIN SYNTHESIS INHIBITION; REVIEW; TEST MEAL;

EID: 36448982145     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. [ADA] ADA Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20:1183-97.
2. [ADA] ADA Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 2003. Report of the Expert Cornmittee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 26:S5-20.
3. Anderson RA, Evans ML, Ellis GR, et al. 2001. The relationship between post-prandial lipeemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis, 154:475-83.
4. Anderson EA, Hoffman RP, Balon TW, et al. 1991. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest, 87:2246-52.
5. Anderson TJ, Meredith IT, Yeung AC, et al. 1995. The effect of cholesterol-lowering and antioxidant therapy on endothelial-dependent coronary vasomotion. N Engl J Med, 332:488-93.
6. Arnlov J, Lind L, Zethelius B, et al. 2001. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J, 142:720-4.
7. Arnlov J, Lind L, Sundstrom J, et al. 2005. Insulin resistance, dietary fat intake and blood pressure predict left ventricular diastolic dysfunction 20 years later. Nutr Metab Cardiovasc Dis, 15:242-9.
8. Avignon A, Radauccanu A, Monnier L. 1997. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care, 20:1822-6.
9. Axelsen M, Smith U, Eriksson JW, et al. 1999. Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med, 131:27-31.
10. Bae JH, Bassenge E, Kim KB, et al. 2001. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis, 155:517-23.
11. Belchetz PE, Plant TM, Nakai Y, et al. 1978. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science, 202:631-3.
12. Bell DS. 2003. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care, 26:2433-41.
13. Bo S, Gambino R, Uberti B, et al. 2005. Does C-reactive protein identify a subclinical metabolic disease in healthy subjects? Eur J Clin Invest, 35:265-70.
14. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414:813-19.
15. Bruttomesso D, Iori E, Kiwanuka E, et al. 2001. Insulin infusion normalizes fasting and post-prandial albumin and fibrinogen synthesis in type 1 diabetes mellitus. Diabet Med, 18:915-20.
16. Ceriello A. 1997. Fibrinogen and diabetes mellitus. Is it time for intervention trials? Diabetologia, 40:731-4.
17. Ceriello A. 2000. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev, 16:125-32.
18. Ceriello A. 2002. Nitrotyrosine: new findings as a marker of postprandial oxidative stress. Int J Clin Pract Suppl, 129:51-8.
19. Ceriello A. 2003. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia, 46:M9-16.
20. Ceriello A, Bortolotti N, Motz E, et al. 1999. Meal-induced oxidative stress and low-density lipoprotein (LDL) oxidation in diabetes: the possible role of hyperglycemia. Metabolism, 48:1503-8.
21. Ceriello A, Bortolotti N, Motz E, et al. 1998. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care, 21:1529-33.
22. Ceriello A, Giugliano D, Quatraro A, et al. 1991. Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci (Colch), 81:739-42.
23. Ceriello A, Giugliano D, Quatraro A, et al. 1988. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia, 31:889-91.
24. Ceriello A, Taboga C, Tonutti L, et al. 1996. Post-meal coagulation activation in diabetes mellitus: the effect of Acarbose. Diabetologia, 39:469-73.
25. Ceriello A, Quagliaro L, Piconi L, et al. 2004. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes, 53:701-10.
26. Charlesworth JA, Kriketos AD, Jones JE, et al. 2005. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metab Clin Exp, 54:821-8.
27. Correia NC, Guarino MP, Paposo J, et al. 2002. Hepatic guanylyl cyclase inhibition induces HISS-dependent insulin resistance. Proc West Pharmacol Soc, 45:57-8.
28. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. 1999. Glucose tolerance and mortality comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 354:617-21.
29. DECODE Study Group, the European Diabetes Epidemiology Group. 2001. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med, 161:397-404.
30. DECODE Study Group, the European Diabetes Epidemiology Group. 2003. Is the current definition for diabetes relevant to mortality risk form all causes and cardiovascular and noncardiovascular disease? Diabetes Care, 26:688-96.
31. DeFronzo RA, Cooke CR, Andres R, et al. 1975. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest, 55:845-55.
32. Dessein PH, Joffe BI, Stanwix AE. 2005. Editorial: Should we evaluate insulin sensitivity in rheumatoid arthritis? Sem Arth Rheum, 35:5-7.
33. De Vegt F, Dekker JM, Ruhe HG, et al. 1999. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia, 42:926-31.
34. Devereux RB, Roman MJ, Paranicas M, et al. 2000. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation, 101:2271-6.
35. Diwadkar VA, Anderson JW, Bridges SR, et al. 1999. Postprandial low density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med, 222:178-84.
36. Dokras A, Bochner M, Hollinrake E. 2005. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol, 106:131-7.
37. Dunn EJ, Grant PJ. 2005. Type 2 diabetes: an atherothrombotic syndrome. Curr Molec Med, 5:323-32.
38. Eliasson B, Mero N, Taskinen M-R, et al. 1997. The insulin resistance syndrome and postprandial lipid intolerance in smokers. Atherosclerosis, 129:79-88.
39. Engelgau MM, Narayan KMV, Herman WH. 2000. Screening for type 2 diabetes. Diabetes Care, 23:1563-80.
40. Festa A, D'Agostino Jr R, Howard G, et al. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 102:42-7.
41. Fishel MA, Watson S, Montine TJ, et al. 2005. Hyperinsulinemia provokes synchronous increases in central inflammation and β-amyloid in normal adults. Arch Neurol, 62:1539-44.
42. Ford ES, Abbasi F, Reaven GM. 2005. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis, 181:143-8.
43. Frantz S, Calvillo L, Tillmanns J, et al. 2005. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the α-glucosidase inhibitor acarbose. FASEB J, 19:591-3.
44. Gaboury CL, Simonson DC, Seely EW, et al. 1994. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest, 94:2295-300.
45. Griendling KK, Alexander RW. 1997. Oxidative stress and cardiovascular disease. Circulation, 96:3264-5.
46. Guarino MP, Afonso RA, Raimundo N, et al. 2003. Hepatic glutathione and nitric oxide are critical for hepatic insulin-sensitizing substance action. Am J Physiol Gastrointest Liver Physiol, 284:G588-94.
47. Guarino MP, Correia NC, Lautt WW, et al. 2004. Insulin sensitivity is mediated by the activation of the Ach/NO/cGMP pathway in rat liver. Am J Physiol Gastrointest Liver Physiol, 287:G527-32.
48. Haffner SM. 1998. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine Rev, 19:583-92.
49. Hanefeld M, Fischer S, Julius U, et al. 1996. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia, 39:1577-83.
50. Holmany A, Yoshida N, Jennische E, et al. 1996. The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Invest, 26:973-8.
51. Hwu CN, Kwok CF, Kuo CS, et al. 2002. Exacerbation of insulin resistance and postprandial triglyceride response in newly diagnosed hypertensive patients with hypertriglyceridaemia. J Human Hypertens, 16:487-93.
52. Ingelsson E, Sundstrom J, Amlow J, et al. 2005. Insulin resistance and risk of congestive heart failure. JAMA, 294:334-41.
53. Kannel WB, Belanger AJ. 1991. Epidemiology of heart failure. Am Heart J, 121:951-7.
54. Karelis AD, Faraj M, Bastard JP, et al. 2005. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab, 90:4145-50.
55. Koenig W, Lowel H, Baumert J, et al. 2004. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation, 109:1349-53.
56. Kravariti M, Naka KK, Kalantaridou SN, et al. 2005. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab, 90:5088-95.
57. Lamonte MJ, Ainsworth BE, Durstine JL. 2005. Influence of cardiorespiratory fitness on the association between C-reactive protein and metabolic syndrome prevalence in racially diverse women. J Women's Hlth, 14:233-9.
58. Lautt WW. 1999. The HISS story overview: A novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetes. Can J Physiol Pharmacol, 77:553-62.
59. Lautt WW 2003. Practice and principles of pharmacodynamic determination of HISS-dependent and HISS-independent insulin action: methods to quantitate mechanisms of insulin resistance. Med Res Rev, 23:1-14.
60. Lautt WW. 2004. A new paradigm for diabetes and obesity: the hepatic insulin sensitizing substance (HISS) hypothesis. J Pharmacol Sci, 95:9-17.
61. Lautt WW, Legate DJ, Reid MAG, et al. 2005. Alcohol suppresses meal-induced insulin sensitization (MIS). Metab Synd Rel Disord, 3:51-9.
62. Lautt WW, Macedo MP, Sadri P, et al. 2001. Hepatic parasympathetic nerve-dependent control of peripheral insulin sensitivity is determined by feeding and fasting: dynamic control of HISS-dependent insulin action. Am J Physiol Gastrointest Liver Physiol, 281:G29-36.
63. Lautt WW, Wang X, Sadri P, et al. 1998. Rapid insulin sensitivity test (RIST). Can J Physiol Pharmacol, 76:1080-6.
64. Lee WY, Park JS, Noh WY, et al. 2004. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol, 97:101-6.
65. Levantesi G, Macchia A, Marfisi RM, et al. 2005. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol, 46:277-83.
66. Levine GN, Frei B, Koulouris SN, et al. 1996. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation, 93:1107-13.
67. Mero N, Syvanne M, Taskinen M-R. 1998. Postprandial lipid metabolism in diabetes. Atherosclerosis, 141:S53-5.
68. Ming Z, Fan Y-J, Yang X, et al. 2006. Synergistic protection by S-adenosylmethionine with vitamins C and E on liver injury induced by thioacetamide in rats. Free Rad Biol Med, 40:617-24.
69. Moller DE. 2001. New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 414:821-7.
70. Moore MC, Satake S, Baranowski B, et al. 2002. Effect of hepatic denervation on peripheral insulin sensitivity in conscious dogs. Am J Physiol Endocrinol Metab, 282:E286-96.
71. Nakazono K, Watanabe N, Matsuno K, et al. 1991. Does superoxide underlie the pathogenesis of hypertension? Proc Nad Acad Sci USA, 88:10045-8.
72. Pai JK, Pischon T, Ma J, et al. 2004. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med, 351:2599-610.
73. Patarrao RS, Lautt WW, Guarino MP, et al. 2005. Atropine inhibits post-prandial insulin sensitivity in a dose dependent manner. Diabetologia, 48:A211.
74. Pearson TA, Mensah GA, Alexander RW, et al. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107:499-511.
75. Reid MAG, Latour MG, Legare DJ, et al. 2002. Comparison of the rapid insulin sensitivity test (RIST), the insulin tolerance test (ITT), and the hyperinsulinemic euglycemic clamp (HIEC) to measure insulin action in rats. Can J Physiol Pharmacol, 80:811-18.
76. Reid MAG, Lautt WW. 2004. Pattern of insulin delivery affects HISS action and insulin resistance. Can J Physiol Pharmacol, 82:1068-1074.
77. Rifai N. 2005. High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome. Clin Chem, 51:504-5.
78. Rosen PT, Ballhausen T, Bloch W, et al. 1995. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia, 38:1157-68.
79. Rutter MK, Meigs JB, Sullivan LM. 2004. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation, 110:380-5.
80. Rutter MK, Parise H, Benjamin EJ, et al. 2003. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation, 107:448-54.
81. Sadri P, Lautt WW. 1999. Blockade of hepatic nitric oxide synthase causes insulin resistance. Am J Physiol, 277:G101-9.
82. Sadri P, Reid MAG, Afonso RA, et al. 2006. Meal-induced insulin sensitization in conscious and anesthetized rat models comparing liquid mixed meal with glucose and sucrose. Br J Nutr, 95:288-95.
83. Sartori M, Ceolotto G, Papparella I, et al. 2004. Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens, 17:604-10.
84. Schchiri M, Kishikawa H, Ohkubo Y, et al. 2000. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 23:B21-9.
85. Scognamiglio R, Negut C, Vigili De Kreutzenberg S, et al. 2005. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation, 112:179-84.
86. Shaw JE, Hodge AM, de Courten M, et al. 1999. Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia, 42:1050-4.
87. Simon C, Brandenberger G. 2002. Ultradian oscillations of insulin secretion in humans. Diabetes, 51:S258-61.
88. Simon C, Follenius M, Brandenberger G. 1987. Postprandial oscillations of plasma glucose insulin and C-peptide in man. Diabetologia, 30:769-73.
89. Solzbach U, Hornng B, Jeserich M, et al. 1997. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation, 96:1513-19.
90. Somogyi A, Ruzicska E, Blazovics A, et al. 2005. Insulin treatment decreases the antioxidant defense mechanism in experimental diabetes. Med Sci Monit, 11:BR206-11.
91. Sundstrom J, Lind L, Nystrom N, et al. 2000. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation, 101:2595-600.
92. Takayama S, Legate DJ, Lautt WW. 2000. Dose-related atropine-induced insulin resistance: comparing intraportal versus intravenous administration. Proc West Pharmacol Soc, 43:33-4.
93. Tse TF, Clutter WE, Shah SD, et al. 1983. Neuroendocrine responses to glucose ingestion in man: specificity, temporal relationships, and quantitative aspects. J Clin Invest, 72:270-7.
94. Unno T, Tago M, Suzuki Y, et al. 2005. Effect of tea catechins on postprandial plasma lipid responses inhuman subjects. Br J Nutr, 93:543-7.
95. Ursini F, Zamburlini A, Cazzolato G, et al. 1998. Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis. Free Rad Biol Med, 25:250-2.
96. Vaccaro O, Ruffa G, Imperatore G, et al. 1999. Risk of diabetes in the new diagnostic category of impaired fasting glucose. Diabetes Care, 22:1490-3.
97. Van De Borne P, Hausberg M, Hoffman RF, et al. 1999. Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Am J Physiol, 276:R178-83.
98. Van Oostrom AJHHM, Sijmonsma TP, Rabelink TJ, et al. 2003. Postprandial leukocyte increase in healthy subjects. Metabolism, 52:199-202.
99. Wannamethee SG, Lowe GDO, Shaper AG, et al. 2004. Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease. Diabetologia, 47:1557-65.
100. Whiteside CI. 2005. Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species. Curr Hypertens Rep, 7:148-54.
101. Xie H, Lautt WW. 1995. Induction of insulin resistance by cholinergic blockade with atropine in the cat. J Auton Pharmacol, 15:361-9.
102. Xie H, Lautt WW. 1996a. Insulin resistance of skeletal muscle produced by hepatic parasympathetic interruption. Am J Physiol, 270:E858-63.
103. Xie H, Lautt WW. 1996b. Insulin resistance caused by hepatic cholinergic interruption and reversed by acetylcholine administration. Am J Physiol, 271:E587-92.
104. Xie H, Tsybenko VA, Johnson MV, et al. 1993. Insulin resistance of glucose response produced by hepatic denervations. Can J Physiol Pharmacol, 71:175-8.
105. Zethelius B, Lithell H, Hales CN, et al. 2005. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year-old men using the euglycaemic insulin clamp. Diabetologia, 48:862-7.
106. Zilversmit DB. 1979. Atherogenesis: a post-prandial phenomenon. Circulation, 60:473-85.
107. Zsuga J, Tory K, Jaszlits L, et al. 2004. Pre-clinical methods for the determination of insulin sensitivity. J Biochem Biophys Meth, 61:253-8.